A Prognostic Risk Signature Based on Myeloid-Derived Suppressor Cells and Regulatory T Cells in Clear Cell Renal Cell Carcinoma
Technology in Cancer Research & Treatment · 2025
DOI: 10.1177/15330338251382839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2025. Verfasst von Zhaoyu Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of urology, Lishui Hospital of Wenzhou Medical University, Lishui People's Hospital, Lishui, Zhejiang, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Biomarkers, Tumor, Kidney Neoplasms, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lishui Welfare Technology Application Research Project.
Abstract (Originalsprache)
Introduction
Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of renal carcinoma. To diagnose ccRCC and assess its prognosis more accurately, it is essential to screen novel prognostic biomarkers and construct prognostic signatures.
Methods
Immune infiltration analysis of the TCGA cohort was performed via single-sample gene set enrichment analysis (ssGSEA). The ccRCC cohort from the TCGA database was used to identify MDSC/Treg-related genes. Hub genes were selected from the common genes in the MDSC/Treg-related gene list via machine learning approaches. These hub genes were then employed to construct the risk signature through multivariate analysis.The prognostic performance, immune performance, and functional analysis of the signature were comprehensively assessed. Two independent GEO datasets were used to verify the major findings above. Potential drugs were screened to promote clinical transformation via the CellMiner platform. Finally, the expression levels of six markers were validated through RT–qPCR analysis of clinical tissue samples.
Results
Six MDSC/Treg-related DEGs were identified via machine learning approaches based on the Cancer Genome Atlas cohort. A novel signature (risk score = −0.5579* wdfy4 -0.2198* il16 + 0.8014* fcgr1b + 0.3344* nod2 + 0.4111* relt + 0.1131* mki67 ) was subsequently constructed. More advanced clinical subgroups had higher scores. In addition, the signature was an independent prognostic indicator (HR = 2.0, 95% CI: 1.6-2.4, p value 0.05).
Conclusion
A signature related to MDSC/Treg DEGs was constructed. This signature can differentiate between immune and clinical features, enabling the prediction of both clinical and immunotherapy prognoses. However, some PCR experiments did not fully validate the bioinformatics results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of urology, Lishui Hospital of Wenzhou Medical University, Lishui People's Hospital, Lishui, Zhejiang, China.
- Department of Urology, Wenzhou Medical University, Lishui, Zhejiang, China.
- Department of emergency surgery, Lishui Hospital of Wenzhou Medical University, Lishui People's Hospital, Lishui, Zhejiang, China.
ORCID-Profile: Junjie Ye
Förderung
- Lishui Welfare Technology Application Research Project
Zitieren
APA
Xu, Z., Liu, K., Xu, Q., Li, P., Wu, Q., & Ye, J. (2025). A Prognostic Risk Signature Based on Myeloid-Derived Suppressor Cells and Regulatory T Cells in Clear Cell Renal Cell Carcinoma. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338251382839
Vancouver
Xu Z, Liu K, Xu Q, Li P, Wu Q, Ye J. A Prognostic Risk Signature Based on Myeloid-Derived Suppressor Cells and Regulatory T Cells in Clear Cell Renal Cell Carcinoma. Technology in Cancer Research & Treatment. 2025. doi:10.1177/15330338251382839
BibTeX
@article{Xu2025,
author = {Xu, Zhaoyu and Liu, Ken and Xu, Qiangqiang and Li, Peng and Wu, Qi and Ye, Junjie},
title = {A Prognostic Risk Signature Based on Myeloid-Derived Suppressor Cells and Regulatory T Cells in Clear Cell Renal Cell Carcinoma},
journal = {Technology in Cancer Research & Treatment},
year = {2025},
doi = {10.1177/15330338251382839}
}
EUVIMED